1. Home
  2. ALUR vs CVKD Comparison

ALUR vs CVKD Comparison

Compare ALUR & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ALUR

Allurion Technologies Inc.

HOLD

Current Price

$1.68

Market Cap

15.4M

Sector

N/A

ML Signal

HOLD

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

BUY

Current Price

$10.02

Market Cap

18.4M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
ALUR
CVKD
Founded
2009
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.4M
18.4M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
ALUR
CVKD
Price
$1.68
$10.02
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$9.25
$32.00
AVG Volume (30 Days)
506.0K
27.5K
Earning Date
11-12-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$17,208,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$9.02
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.02
$8.12
52 Week High
$16.81
$22.90

Technical Indicators

Market Signals
Indicator
ALUR
CVKD
Relative Strength Index (RSI) 54.37 44.66
Support Level $1.37 $8.12
Resistance Level $1.79 $11.58
Average True Range (ATR) 0.18 0.87
MACD 0.06 0.02
Stochastic Oscillator 88.31 50.24

Price Performance

Historical Comparison
ALUR
CVKD

About ALUR Allurion Technologies Inc.

Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Share on Social Networks: